Abstract
In recent years, inhibitors of angiogenesis have become a focus of clinical trials aimed at expanding treatment options for women afflicted with epithelial ovarian cancer (EOC). Bevacizumab, a VEGF inhibitor, has been well studied in multiple solid tumors, suggesting progression-free and overall survival benefits. In EOC, bevacizumab has been the subject of many trials with results indicating a progression-free survival benefit in a variety of settings. The addition of bevacizumab to the EOC armamentarium, however, is not without risk. This article provides a rationale for targeting angiogenesis and discusses pivotal trials evaluating the utility of bevacizumab in EOC. Current research is evaluating optimal dosing duration, benefit of bevacizumab beyond progression, biomarkers to direct anti-angiogenic therapy and patient reported outcomes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
